Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and Joint Broker, at 11.00am BST on 3 June 2021. Destiny Pharma will operate an audio dial-in facility to allow Shareholders to listen to the business of the meeting.
As previously announced in the Posting of Annual Report and Notice of AGM, whilst in normal circumstances the Board values the opportunity to engage with shareholders in person at its AGM, on this occasion the Board feels it is appropriate to advise shareholders against travelling to attend the AGM in person and, instead, to submit proxy votes as early as possible because, as matters currently stand, shareholders will not be granted access to the AGM. Shareholders are strongly advised to appoint the Chairman of the AGM as their proxy.
Immediately following the AGM at 11:00am BST, Destiny Pharma will host a live webcast presentation followed by Q&A.
Shareholders will not get an opportunity to vote or ask questions or any other participation during the call but are encouraged to pre-submit any questions for Directors of the Company in advance of the AGM to email@example.com by no later than 17:00pm BST on 2 June, 2021. Please include the Shareholder’s name and Shareholder Reference Number (which can be found on the share certificate or proxy form) in your email.
A full recording of the 2021 AGM will be made available on the Company’s website at www.destinypharma.com
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
Optimum Strategic Communications
Mary Clark, Shabnam Bashir, Manel Mateus
+44 (0) 203 174 1789
finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the company, please visit https://www.destinypharma.com